EGFR and glioblastoma: Notably, based on our current and previous study (19), we can conclude that LRIG3 exerts no effects on EGFR and MET protein expression levels, but does regulate the phosphorylation of MET and EGFR signaling pathway components to inhibit the progression of glioblastoma.